サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1386214

白血病治療の世界市場：動向、予測、競合分析（～2030年）

Leukemia Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

白血病治療の世界市場：動向、予測、競合分析（～2030年）
出版日: 2023年10月03日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

白血病治療の動向と予測

世界の白血病治療の市場規模は、2024～2030年にかけてCAGR 8.4%で成長し、2030年までに約214億6,000万米ドルに達すると予測されています。この市場の主な促進要因は、白血病の罹患率の増加、白血病のより効果的な治療に対するニーズの高まり、ヘルスケア業界における研究開発費の増加です。世界の白血病治療市場の将来は、病院薬局、ドラッグストアや小売薬局、オンラインプロバイダー市場にビジネスチャンスがあり、有望視されています。

白血病治療市場の洞察

Lucintelは、慢性リンパ性白血病に対する製品承認の増加と慢性リンパ性白血病に対する白血病治療の存在により、予測期間中、慢性リンパ性白血病が最大のセグメントであり続けると予測しています。

この市場において、病院薬局は、白血病とその治療オプションに関する一般市民の意識の高まりと、病院での治療を求める人々の増加により、最大のセグメントであり続けると思われます。

北米は、白血病治療のための再生医療分野での研究の増加や個別化医療に対する意識の高まりから、予測期間中に最も高い成長が見込まれています。

市場規模・推計：白血病治療の市場規模を金額（10億米ドル）で推計

動向と予測分析：各種セグメント別、地域別の市場動向（2018～2023年）と予測（2024～2030年）

セグメント別分析：白血病治療市場規模をタイプ別、薬剤別、流通チャネル別、地域別に金額（10億米ドル）で推計

地域別分析：白血病治療市場の北米、欧州、アジア太平洋、その他の地域の内訳

成長機会：白血病治療市場のタイプ、薬剤、流通チャネル、地域別の成長機会分析

戦略的分析：白血病治療市場のM&A、新製品開発、競合情勢など

ポーターのファイブフォースモデルに基づく業界の競合強度分析

本レポートは以下の11の主要な質問に回答しています：

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
  • Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
  • Q.3.今後成長が加速すると思われる地域とその理由は？
  • Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
  • Q.5.この市場におけるビジネスリスクと競合の脅威は？
  • Q.6.この市場における新たな動向とその理由は？
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は？
  • Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界の白血病治療市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 市場動向と予測分析：2018～2030年

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界の白血病治療市場の動向（2018～2023年）と予測（2024～2030年）
  • 世界の白血病治療市場：タイプ別
    • 急性リンパ性白血病
    • 急性骨髄性白血病
    • 慢性リンパ性白血病
    • 慢性骨髄性白血病
    • その他
  • 世界の白血病治療市場：薬剤別
    • 化学療法
    • 標的療法・免疫療法
  • 世界の白血病治療市場：流通チャネル別
    • 病院薬局
    • ドラッグストア・小売薬局
    • オンラインプロバイダー

第4章 市場動向と予測分析：地域別（2018～2030年）

  • 世界の白血病治療市場：地域別
  • 北米の白血病治療市場
  • 欧州の白血病治療市場
  • アジア太平洋の白血病治療市場
  • その他の地域の白血病治療市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • タイプ別の世界の白血病治療市場の成長機会
    • 薬剤別の世界の白血病治療市場の成長機会
    • 流通チャネル別の世界の白血病治療市場の成長機会
    • 地域別の世界の白血病治療市場の成長機会
  • 世界の白血病治療市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の白血病治療市場の能力拡大
    • 世界の白血病治療市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Bristol-Myers Squibb
  • Takeda Pharmaceutical
  • Lupin
  • Gilead Sciences
  • Novartis
  • Amgen
  • Teva Pharmaceutical Industries
  • Abbvie
  • Pfizer
  • Sanofi
目次

Leukemia Therapeutics Trends and Forecast

The future of the global leukemia therapeutics market looks promising with opportunities in the hospital pharmacies, drug store and retail pharmacies, and online provider markets. The global leukemia therapeutics market is expected to reach an estimated $21.46 billion by 2030 with a CAGR of 8.4% from 2024 to 2030. The major drivers for this market are growing incidence of leukemia, increasing need for more effective treatment for lukemia and rising R&D spending in the healthcare industry.

A more than 150-page report is developed to help in your business decisions.

Leukemia Therapeutics by Segment

The study includes a forecast for the global leukemia therapeutics by type, drug, distribution channel, and region.

Leukemia Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Acute Lymphocytic Leukemia
  • Acute Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Others

Leukemia Therapeutics Market by Drug [Shipment Analysis by Value from 2018 to 2030]:

  • Chemotherapy
  • Targeted Therapy and Immunotherapy

Leukemia Therapeutics Market by Distribution channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Drug Store and Retail Pharmacies
  • Online Providers

Leukemia Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Leukemia Therapeutics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies leukemia therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the leukemia therapeutics companies profiled in this report include-

  • Bristol-Myers Squibb
  • Takeda Pharmaceutical
  • Lupin
  • Gilead Sciences
  • Novartis
  • Amgen
  • Teva Pharmaceutical Industries
  • Abbvie
  • Pfizer
  • Sanofi

Leukemia Therapeutics Market Insights

Lucintel forecasts that chronic lymphocytic leukemia will remain the largest segment over the forecast period due to increase in product approvals for chronic lymphocytic leukemia and presence of leukemia therapeutics for chronic lymphocytic leukemia.

Within this market, hospital pharmacies will remain the largest segment due to growing public awareness regarding leukemia and its treatment options along with increasing number of people seeking treatment in hospitals.

North America is expected to witness highest growth over the forecast period due to growing research in the field of regenerative medicine for the treatment of leukemia and rising awareness on personalized medicine in the region.

Features of the Global Leukemia Therapeutics Market

Market Size Estimates: Leukemia therapeutics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Leukemia therapeutics market size by type, drug, distribution channel, and region in terms of value ($B).

Regional Analysis: Leukemia therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, drugs, distribution channels, and regions for the leukemia therapeutics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the leukemia therapeutics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the leukemia therapeutics market size?

Answer: The global leukemia therapeutics market is expected to reach an estimated $21.46 billion by 2030.

Q.2 What is the growth forecast for leukemia therapeutics market?

Answer: The global leukemia therapeutics market is expected to grow with a CAGR of 8.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the leukemia therapeutics market?

Answer: The major drivers for this market are growing incidence of leukemia, increasing need for more effective treatment for lukemia and rising R&D spending in the healthcare industry.

Q4. What are the major segments for leukemia therapeutics market?

Answer: The future of the leukemia therapeutics market looks promising with opportunities in the hospital pharmacies, drug store and retail pharmacies, and online provider markets.

Q5. Who are the key leukemia therapeutics market companies?

Answer: Some of the key leukemia therapeutics companies are as follows:

  • Bristol-Myers Squibb
  • Takeda Pharmaceutical
  • Lupin
  • Gilead Sciences
  • Novartis
  • Amgen
  • Teva Pharmaceutical Industries
  • Abbvie
  • Pfizer
  • Sanofi

Q6. Which leukemia therapeutics market segment will be the largest in future?

Answer: Lucintel forecasts that chronic lymphocytic leukemia will remain the largest segment over the forecast period due to increase in product approvals for chronic lymphocytic leukemia and presence of leukemia therapeutics for chronic lymphocytic leukemia.

Q7. In leukemia therapeutics market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to growing research in the field of regenerative medicine for the treatment of leukemia and rising awareness on personalized medicine in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the leukemia therapeutics market by type (acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia,chronic myeloid leukemia, and others), drug (chemotherapy, and targeted therapy & immunotherapy), distribution channel (hospital pharmacies, drug store and retail pharmacies, and online providers), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Leukemia Therapeutics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Leukemia Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Leukemia Therapeutics Market by Type
    • 3.3.1: Acute Lymphocytic Leukemia
    • 3.3.2: Acute Myeloid Leukemia
    • 3.3.3: Chronic Lymphocytic Leukemia
    • 3.3.4: Chronic Myeloid Leukemia
    • 3.3.5: Others
  • 3.4: Global Leukemia Therapeutics Market by Drug
    • 3.4.1: Chemotherapy
    • 3.4.2: Targeted Therapy and Immunotherapy
  • 3.5: Global Leukemia Therapeutics Market by Distribution channel
    • 3.5.1: Hospital Pharmacies
    • 3.5.2: Drug Store and Retail Pharmacies
    • 3.5.3: Online Providers

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Leukemia Therapeutics Market by Region
  • 4.2: North American Leukemia Therapeutics Market
    • 4.2.2: North American Leukemia Therapeutics Market by Distribution channel: Hospital Pharmacies, Drug Store and Retail Pharmacies, and Online Providers
  • 4.3: European Leukemia Therapeutics Market
    • 4.3.1: European Leukemia Therapeutics Market by Type: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, and Others
    • 4.3.2: European Leukemia Therapeutics Market by Distribution channel: Hospital Pharmacies, Drug Store and Retail Pharmacies, and Online Providers
  • 4.4: APAC Leukemia Therapeutics Market
    • 4.4.1: APAC Leukemia Therapeutics Market by Type: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, and Others
    • 4.4.2: APAC Leukemia Therapeutics Market by Distribution channel: Hospital Pharmacies, Drug Store and Retail Pharmacies, and Online Providers
  • 4.5: ROW Leukemia Therapeutics Market
    • 4.5.1: ROW Leukemia Therapeutics Market by Type: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, and Others
    • 4.5.2: ROW Leukemia Therapeutics Market by Distribution channel: Hospital Pharmacies, Drug Store and Retail Pharmacies, and Online Providers

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Leukemia Therapeutics Market by Type
    • 6.1.2: Growth Opportunities for the Global Leukemia Therapeutics Market by Drug
    • 6.1.3: Growth Opportunities for the Global Leukemia Therapeutics Market by Distribution channel
    • 6.1.4: Growth Opportunities for the Global Leukemia Therapeutics Market by Region
  • 6.2: Emerging Trends in the Global Leukemia Therapeutics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Leukemia Therapeutics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Leukemia Therapeutics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Bristol-Myers Squibb
  • 7.2: Takeda Pharmaceutical
  • 7.3: Lupin
  • 7.4: Gilead Sciences
  • 7.5: Novartis
  • 7.6: Amgen
  • 7.7: Teva Pharmaceutical Industries
  • 7.8: Abbvie
  • 7.9: Pfizer
  • 7.10: Sanofi